Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

OBJECTIVES: Humoral vaccine responses to SARS-CoV-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMID) following two vaccine doses. To protect these vulnerable patients against severe COVID-19 disease, a three-dose primary vaccination strategy has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Syversen, Silje Watterdal, Jyssum, Ingrid, Tveter, Anne Therese, Sexton, Joe, Christensen, Ingrid Egeland, Tran, Trung T, Bjørlykke, Kristin Hammersbøen, Mjaaland, Siri, Warren, David J, Kvien, Tore K, Chopra, Adity, Kro, Grete Birkeland, Jahnsen, Jorgen, Munthe, Ludvig A, Haavardsholm, Espen A, Grødeland, Gunnveig, Vaage, John Torgils, Provan, Sella Aarrestad, Jørgensen, Kristin Kaasen, Goll, Guro Løvik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Inflammatory Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638754/
https://www.ncbi.nlm.nih.gov/pubmed/36328399
http://dx.doi.org/10.1136/rmdopen-2022-002417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638754/
https://www.ncbi.nlm.nih.gov/pubmed/36328399
http://dx.doi.org/10.1136/rmdopen-2022-002417

Ejemplares similares